Clinical Trial Update: An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

View source ↗

Summary

An observational study update comparing Rituximab and other TNF inhibitors in rheumatoid arthritis patients who did not respond adequately to a prior TNF inhibi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CIMZIA (CERTOLIZUMAB PEGOL)
• ENBREL (etanercept)
• Humira (adalimumab)
• MabThera (rituximab)
• Remicade (infliximab)
• Rituxan (rituximab)
• Simponi (golimumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Status: COMPLETED | Results posted: 2017-01-24